| Dr Sirisha Donepudi, MD | |
|
1040 Delaware Ave, Marion, OH 43302-6416 | |
| (740) 375-6492 | |
| (740) 375-8166 |
| Full Name | Dr Sirisha Donepudi |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 26 Years |
| Location | 1040 Delaware Ave, Marion, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023073806 | NPI | - | NPPES |
| 2298556 | Medicaid | OH |
| Facility Name | Location | Facility Type |
|---|---|---|
| Marion General Hospital | Marion, OH | Hospital |
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Grady Memorial Hospital | Delaware, OH | Hospital |
| Hardin Memorial Hospital | Kenton, OH | Hospital |
| Morrow County Hospital | Mount gilead, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Marion Area Physicians Llc | 1850549437 | 149 |
News Archive
An international team co-led by scientists from the University of Michigan have discovered 12 more regions on the genome with DNA variants that are associated with increased risk of type 2 diabetes, bringing the number to 38.
Two immune system proteins could be the culprit behind many lupus patients' resistance to widely used steroid treatments, scientists with the Baylor Research Institute in Dallas announced today. It is estimated that more than 5 million people suffer from lupus worldwide.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
When you see a familiar face, when a bird-watcher catches a glimpse of a rare bird perched on a limb, or when a car-fancier spots a classic auto driving past, the same small region in the brain becomes engaged.
› Verified 4 days ago
| Entity Name | Marion Area Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619230802 PECOS PAC ID: 1850549437 Enrollment ID: O20120925000053 |
News Archive
An international team co-led by scientists from the University of Michigan have discovered 12 more regions on the genome with DNA variants that are associated with increased risk of type 2 diabetes, bringing the number to 38.
Two immune system proteins could be the culprit behind many lupus patients' resistance to widely used steroid treatments, scientists with the Baylor Research Institute in Dallas announced today. It is estimated that more than 5 million people suffer from lupus worldwide.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
When you see a familiar face, when a bird-watcher catches a glimpse of a rare bird perched on a limb, or when a car-fancier spots a classic auto driving past, the same small region in the brain becomes engaged.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sirisha Donepudi, MD L-3549, Columbus, OH 43260-0001 Ph: (740) 383-7927 | Dr Sirisha Donepudi, MD 1040 Delaware Ave, Marion, OH 43302-6416 Ph: (740) 375-6492 |
News Archive
An international team co-led by scientists from the University of Michigan have discovered 12 more regions on the genome with DNA variants that are associated with increased risk of type 2 diabetes, bringing the number to 38.
Two immune system proteins could be the culprit behind many lupus patients' resistance to widely used steroid treatments, scientists with the Baylor Research Institute in Dallas announced today. It is estimated that more than 5 million people suffer from lupus worldwide.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
When you see a familiar face, when a bird-watcher catches a glimpse of a rare bird perched on a limb, or when a car-fancier spots a classic auto driving past, the same small region in the brain becomes engaged.
› Verified 4 days ago
Dr. Joseph M. Sutton, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1040 Delaware Ave, Marion, OH 43302 Phone: 740-383-7980 Fax: 740-383-3040 | |
Arvinder S Bhinder, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1050 Delaware Ave, Marion, OH 43302 Phone: 740-383-7830 Fax: 740-383-7067 | |
Veera Chandra Sekhar Veerla, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1000 Mckinley Park Dr, Marion, OH 43302 Phone: 740-383-8473 | |
Vivek Rajan Awasty, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 980 S Prospect St, Suite 2, Marion, OH 43302 Phone: 740-383-7250 Fax: 740-387-8416 | |
Sudesh S Reddy, MD INC Endocrinology, Diabetes & Metabolism Medicare: May Accept Medicare Assignments Practice Location: 402 S State St, Marion, Marion, OH 43302 Phone: 740-387-0650 | |
Dr. Mayank Kantilal Shah, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1051 Harding Memorial Pkwy, Suite A, Marion, OH 43302 Phone: 740-382-6900 Fax: 740-387-0577 |